32 related articles for article (PubMed ID: 1703825)
1. T-TAS
Samanbar S; Piñeyroa JA; Moreno-Castaño AB; Pino M; Torramadé-Moix S; Martinez-Sanchez J; Lozano M; Sanz C; Escolar G; Diaz-Ricart M
Blood Transfus; 2024 Mar; 22(2):166-175. PubMed ID: 38063791
[TBL] [Abstract][Full Text] [Related]
2. How to manage hemostasis in patients with liver disease during interventions.
Roberts LN
Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):274-280. PubMed ID: 38066857
[TBL] [Abstract][Full Text] [Related]
3. The Bleeding Time Test in 2024: A Glorious Past and Current Challenges.
Undas A
Semin Thromb Hemost; 2024 Apr; 50(3):517-519. PubMed ID: 37967834
[No Abstract] [Full Text] [Related]
4. Therapeutic use of phospholipids in thrombocytopenic or thrombocytopathic patients.
Dietrich GV; Söhngen D; Kretschmer V
Semin Thromb Hemost; 1995; 21 Suppl 2():77-8. PubMed ID: 7660162
[TBL] [Abstract][Full Text] [Related]
5. [Short-lasting infusions of Fibraccel following aortocoronary bypass surgery. The effect on postoperative blood loss and hemostasis depending on the time of extracorporeal circulation].
Duda D; Brandt L; Ohler W
Anaesthesist; 1988 Sep; 37(9):588-93. PubMed ID: 3056085
[TBL] [Abstract][Full Text] [Related]
6. Perioperative monitoring of primary and secondary hemostasis in coronary artery bypass grafting.
Hertfelder HJ; Bös M; Weber D; Winkler K; Hanfland P; Preusse CJ
Semin Thromb Hemost; 2005; 31(4):426-40. PubMed ID: 16149021
[TBL] [Abstract][Full Text] [Related]
7. A liposome based platelet substitute, the plateletsome, with hemostatic efficacy.
Rybak ME; Renzulli LA
Biomater Artif Cells Immobilization Biotechnol; 1993; 21(2):101-18. PubMed ID: 8318606
[TBL] [Abstract][Full Text] [Related]
8. Thrombelastography monitoring of platelet substitution therapy and rFVIIa administration in haemato-oncological patients with severe thrombocytopenia.
Salaj P; Marinov I; Marková M; Pohlreich D; Cetkovský P; Hrachovinová I
Prague Med Rep; 2004; 105(3):311-7. PubMed ID: 15782557
[TBL] [Abstract][Full Text] [Related]
9. [Use of phospholipids (Fibraccel) for hemostasis in thrombocytopenic-thrombocytopathic patients].
Dietrich G; Söhngen D; Kretschmer V
Beitr Infusionsther; 1990; 26():183-5. PubMed ID: 1703825
[TBL] [Abstract][Full Text] [Related]
10. The thrombocytopenic rabbit bleeding time model to evaluate the in vivo hemostatic efficacy of platelets and platelet substitutes.
Blajchman MA; Lee DH
Transfus Med Rev; 1997 Apr; 11(2):95-105. PubMed ID: 9140169
[No Abstract] [Full Text] [Related]
11. The hemostatic mechanism and its defects.
Macfarlane RG
Int Rev Exp Pathol; 1968; 6():55-133. PubMed ID: 4884086
[No Abstract] [Full Text] [Related]
12. Use of blood and blood components in canine and feline patients with hemostatic disorders.
de Gopegui RR; Feldman BF
Vet Clin North Am Small Anim Pract; 1995 Nov; 25(6):1387-402. PubMed ID: 8619272
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
